Life Sciences Scotland have interviewed Elasmogen’s CEO Caroline Barelle as part of their Insight series. The article can be accessed here.
Month: January 2019
Elasmogen Licenses NDure™ Half-life Extension Technology to ImmunoForge | 07.01.2019
Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019: Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement to Elasmogen’s proprietary NDure half-life extension technology for use in two non-disclosed targets. ImmunoForge will be responsible […]